Citrus Bioflavonoid
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | Citrus bioflavonoid complex — a mixture, not a single compound |
|---|---|
| Chemical class | Flavanone and flavone glycosides — hesperidin, naringin, eriocitrin, narirutin, diosmin |
| Botanical source | Citrus spp. peel — sweet and bitter orange, grapefruit, lemon |
| CAS | No single CAS — hesperidin 520-26-3, naringin 10236-47-2, diosmin 520-27-4 |
| Assay caution | Colorimetric total-flavonoid methods over-read against HPLC of named compounds |
| Obsolete term | "Vitamin P" — withdrawn; bioflavonoids are not vitamins |
| Claim strength | High for the assay and composition issues; Emerging for the complex itself |
| Buy from Herbuno | Citrus Bioflavonoid 40% Powder · Hesperidin 95% (Citrus aurantium) · Hesperidin 90% Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot; phytosanitary on request |
Name origin: Albert Szent-Györgyi, who had isolated vitamin C, proposed in 1936 that a citrus factor affecting capillary permeability be called vitamin P, for permeability. The designation was withdrawn when it became clear these compounds are not vitamins — no deficiency state exists and they are not dietarily essential. "Bioflavonoid" survives as a commercial term; "vitamin P" should not be used.
Traditional use: Citrus peel has a long record in both Ayurvedic and traditional Chinese practice, where dried mature tangerine peel (chen pi) and immature peel (qing pi) are distinguished and used differently for digestive and respiratory complaints. European use of citrus peel preparations for venous and capillary complaints dates to the mid-twentieth century and led to the semi-synthetic flavonoid pharmaceuticals still registered in several countries.
Research trajectory: The research has moved steadily from the complex toward named isolates, and the evidence has followed it. Early work examined crude peel preparations for capillary fragility. Modern work concerns specific compounds: diosmin and the micronised purified flavonoid fraction in chronic venous insufficiency, where it is a registered medicine in parts of Europe; hesperidin in endothelial and metabolic endpoints; naringin's pharmacokinetic interactions. The complex itself has accumulated comparatively little.
Commercial source: Citrus bioflavonoid is produced from citrus peel, a by-product of juicing, by aqueous or hydroalcoholic extraction and standardisation. Composition depends heavily on the species and the part: sweet orange peel is hesperidin-dominant, bitter orange similar, grapefruit is naringin-dominant, and lemon is relatively rich in eriocitrin. Diosmin is semi-synthetic, produced by oxidation of hesperidin.
Evidence for Citrus Bioflavonoid Applications
Colorimetric total-flavonoid assays over-read, and this is the central commercial problem in the category. Aluminium chloride complexation and other spectrophotometric total-flavonoid methods respond to a wide range of phenolic structures and are commonly calibrated against rutin, which is not a quantitatively significant citrus flavonoid. The result is a figure that can substantially exceed the sum of the named flavonoids present by HPLC. A "40% total bioflavonoids" declaration by colorimetry and a "40% hesperidin" declaration by HPLC are not comparable numbers, and the gap between them is where most disputes in this category sit. Claim strength: High.
Composition varies enough by species and part that "citrus bioflavonoid" is not a specification. Sweet and bitter orange peel are hesperidin-dominant; grapefruit peel is naringin-dominant; lemon peel carries relatively more eriocitrin. Because the individual flavonoids differ in solubility, taste, bioavailability and pharmacological interaction, two materials at the same total-flavonoid assay can behave quite differently. Specify the species, the plant part, and the named flavonoid content by HPLC. Claim strength: High.
Naringin is intensely bitter and interacts with drug transport, which makes a naringin-dominant material a different formulation proposition. Naringin is one of the compounds responsible for grapefruit's bitterness, so a grapefruit-derived material carries a taste burden that an orange-derived one does not. Separately, grapefruit constituents inhibit intestinal CYP3A4 and organic anion transporting polypeptides, producing the well-documented grapefruit drug interaction; furanocoumarins are the principal CYP3A4 inhibitors but naringin contributes to the transporter effects. A naringin-rich material warrants an interaction note. Claim strength: Moderate.
Hesperidin's bioavailability is poor and microbiota-dependent, which limits what the unmodified glycoside can do. Hesperidin is a rutinoside that is not absorbed intact to any useful extent; it requires deglycosylation by colonic bacteria to the aglycone hesperetin before absorption, so plasma appearance is delayed, variable between individuals, and dependent on gut flora. Hesperidin is also very poorly water-soluble. Glucosyl hesperidin, an enzymatically modified derivative, is dramatically more soluble and is a separate article where solubility matters. Claim strength: High.
The clinical evidence belongs to specific isolates rather than to the complex, and should not be transferred. Diosmin, and particularly the micronised purified flavonoid fraction of diosmin with hesperidin, has a substantial controlled-trial literature in chronic venous insufficiency and haemorrhoidal disease, and is a registered medicine in several European markets. Hesperidin has a smaller literature on endothelial function and metabolic markers. A citrus bioflavonoid complex cannot borrow either, and where a customer wants the evidence they should be specifying the isolate. Claim strength: Moderate for diosmin and MPFF; Emerging for the complex.
The vitamin C pairing is conventional rather than evidenced, and worth being honest about. Citrus bioflavonoids are routinely co-formulated with ascorbate on the historical vitamin P reasoning that they enhance vitamin C activity or capillary integrity. That proposition arose before the compounds were characterised and has not been established by modern trials. The combination is harmless and commercially established; presenting it as a demonstrated synergy goes beyond the evidence. Claim strength: Emerging.
Sourcing citrus bioflavonoid from Herbuno. We supply a citrus bioflavonoid complex at 40% and hesperidin isolates at 90% and 95% from Citrus aurantium.
Decide first whether you want a complex or a named compound, because the evidence sits with the isolates. If you take the complex, specify the named flavonoid content by HPLC rather than accepting a colorimetric total-flavonoid figure — those methods are commonly calibrated against rutin, which is not a significant citrus flavonoid, and they over-read. Also specify the species and part, since orange is hesperidin-dominant and grapefruit naringin-dominant, which changes taste and interaction profile. All lots ship with CoA and MSDS; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
Dose on named flavonoid content, not on total bioflavonoids. The diosmin and MPFF venous literature uses 450 to 500 milligrams of the micronised fraction once or twice daily, which is a pharmaceutical rather than a supplement context. Hesperidin studies have generally used 250 to 500 milligrams daily. Citrus bioflavonoid complexes are commonly included at 100 to 500 milligrams, often alongside vitamin C, where the inclusion is conventional rather than dose-ranged. Converting a complex inclusion into a named-flavonoid dose requires the HPLC profile.
The analytical specification is where this category is won or lost. Require individual flavonoid quantification by HPLC — hesperidin, naringin, narirutin, eriocitrin, diosmin as applicable — rather than, or at minimum alongside, any total-flavonoid figure. If a colorimetric total is quoted, require the method and the calibration standard named, because an aluminium chloride method against rutin is not comparable to HPLC against hesperidin. State in the purchase specification which number the price is against.
Formulation handling is dominated by solubility and taste. Hesperidin is very poorly soluble in water and will not dissolve in a beverage at meaningful concentration; glucosyl hesperidin is the soluble alternative and a separate article. Naringin-rich material is intensely bitter and needs a masking strategy planned at formulation rather than added later. The complex is a free-flowing powder, generally pale cream to light brown depending on extraction, and will contribute colour to a pale matrix.
Stability is reasonable with the usual polyphenol caveats. Flavonoid glycosides are more stable than their aglycones and tolerate heat and a moderate pH range adequately, but they are susceptible to oxidative degradation and to discolouration in the presence of trace metals and at alkaline pH. Chelation and pH control help. Hesperidin can crystallise out of a supersaturated system over shelf life, producing visible sediment, so a liquid carrying it near its solubility limit needs real-time stability rather than accelerated data alone.
Standard botanical coverage applies: heavy metals, pesticide residues, microbiological limits, residual solvents with the extraction system named, loss on drying, ash, and the species confirmed by binomial with the plant part stated. For citrus peel material, specify the peel source and whether it is a juicing by-product, and require pesticide residue testing with attention to post-harvest treatments, which concentrate in peel rather than in juice — this is a real difference between peel-derived and pulp-derived citrus materials and is worth a specific request.
Two naming points worth carrying into customer documentation. First, "vitamin P" is an obsolete and withdrawn designation: bioflavonoids are not vitamins, no deficiency state exists, and using the term invites regulatory attention as an implied nutrient claim. Second, "citrus bioflavonoid complex" describes a category rather than an article, so a purchase order using it alone is not a specification — the species, the part, the named flavonoid profile and the assay method together are. Where a customer's objective is an outcome the literature actually supports, the honest recommendation is usually diosmin or the micronised purified flavonoid fraction for venous endpoints, or hesperidin for the endothelial and metabolic work, rather than a complex.
Frequently Asked Questions — Citrus Bioflavonoid
Why does the assay figure matter so much?
Because colorimetric total-flavonoid methods over-read. Aluminium chloride and similar spectrophotometric methods respond to a wide range of phenolics and are commonly calibrated against rutin, which is not a quantitatively significant citrus flavonoid. A "40% total bioflavonoids" figure by colorimetry and "40% hesperidin" by HPLC are not comparable numbers.
Is "citrus bioflavonoid" a specification?
No, it is a category. Sweet and bitter orange peel are hesperidin-dominant, grapefruit is naringin-dominant, lemon carries relatively more eriocitrin — and those differ in solubility, taste, bioavailability and drug interaction. Specify species, plant part, named flavonoid content by HPLC, and the assay method.
Can I use the venous insufficiency evidence?
Not on a complex. That literature belongs to diosmin and specifically to the micronised purified flavonoid fraction of diosmin with hesperidin, which is a registered medicine in several European markets. Hesperidin has its own smaller literature on endothelial and metabolic markers. If a customer wants the evidence, specify the isolate.
Why is hesperidin poorly absorbed?
It is a rutinoside and is not absorbed intact to any useful extent — colonic bacteria must deglycosylate it to hesperetin first, so plasma appearance is delayed, highly variable between individuals and dependent on gut flora. It is also very poorly water-soluble. Glucosyl hesperidin is dramatically more soluble and is a separate article.
Does the vitamin C pairing do anything?
It is conventional rather than demonstrated. The combination comes from the 1930s "vitamin P" reasoning about capillary permeability, which predates characterisation of the compounds and has not been established by modern trials. Harmless and commercially established — but presenting it as a proven synergy overstates it. And "vitamin P" itself is a withdrawn term.
Anything specific to test on peel-derived material?
Pesticide residues, with attention to post-harvest treatments. Those concentrate in peel rather than juice, so a peel-derived citrus extract carries a different residue risk from a pulp-derived one. Worth requesting specifically rather than relying on a generic botanical panel.